昊海生物科技(06826.HK)斥7,000萬人幣購廈門南鵬光學股權及亨泰光學角膜產品代理經銷權
昊海生物科技(06826.HK)公佈,以總對價7,000萬元人民幣(下同),向廈門南鵬集團及李志毅,收購目標公司廈門南鵬光學51%股權,以及亨泰光學於中國供應的硬性角膜接觸鏡及角膜塑形鏡產品(目標產品)的中國獨家代理經銷權。
目標集團主要從事硬性角膜接觸鏡(RGP)及角膜塑形鏡產品的銷售,並享有亨泰光學供應的目標產品於中國的獨家代理經銷權。
完成交易後,目標公司將由公司、受讓方、廈門南鵬集團及李志毅分別擁有51%、40%及9%股權,目標公司將成爲公司的間接非全資附屬。
公司初步測算,預計收購事項將形成500萬至2,500萬元的商譽。另認爲,收購事項將有助集團取得亨泰光學於中國供應的所有產品的獨家代理經銷權,豐富眼科產品組合,快速提升其於近視防控領域的產品及銷售佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.